journal article·2025-01Open access

A Cardiac‐Targeting and Anchoring Bimetallic Cluster Nanozyme Alleviates Chemotherapy‐Induced Cardiac Ferroptosis and PANoptosis

Junyue Xing, Xiaohan Ma, Yanan Yu, Yangfan Xiao, Lu Chen, Weining Yuan, Yingying Wang, Keyu Liu, Zhiping Guo, Hao Tang, Kelong Fan, Wei Jiang

Advanced Science· Volume 12· Issue 1

Abstract

Abstract Doxorubicin (DOX), a potent antineoplastic agent, is commonly associated with cardiotoxicity, necessitating the development of strategies to reduce its adverse effects on cardiac function. Previous research has demonstrated a strong correlation between DOX‐induced cardiotoxicity and the activation of oxidative stress pathways. This work introduces a novel antioxidant therapeutic approach, utilizing libraries of tannic acid and N‐acetyl‐L‐cysteine‐protected bimetallic cluster nanozymes. Through extensive screening for antioxidative enzyme‐like activity, an optimal bimetallic nanozyme (AuRu) is identified that possess remarkable antioxidant characteristics, mimicking catalase‐like enzymes. Theoretical calculations reveal the surface interactions of the prepared nanozymes that simulate the hydrogen peroxide decomposition process, showing that these bimetallic nanozymes readily undergo OH⁻ adsorption and O₂ desorption. To enhance cardiac targeting, the atrial natriuretic peptide is conjugated to the AuRu nanozyme. These cardiac‐targeted bimetallic cluster nanozymes, with their anchoring capability, effectively reduce DOX‐induced cardiomyocyte ferroptosis and PANoptosis without compromising tumor treatment efficacy. Thus, the therapeutic approach demonstrates significant reductions in chemotherapy‐induced cardiac cell death and improvements in cardiac function, accompanied by exceptional in vivo biocompatibility and stability. This study presents a promising avenue for preventing chemotherapy‐induced cardiotoxicity, offering potential clinical benefits for cancer patients.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine Central China Subcenter of National Center for Cardiovascular Diseases Henan Cardiovascular Disease Center Fuwai Central‐China Cardiovascular Hospital Central China Fuwai Hospital of Zhengzhou University Zhengzhou 450046 China

Henan Key Laboratory of Chronic Disease Management Central China Fuwai Hospital of Zhengzhou University Zhengzhou Henan 451464 China

Zhengzhou Key Laboratory of Cardiovascular Aging Central China Fuwai Hospital of Zhengzhou University Zhengzhou Henan 451464 China

Department of Cardiovascular Diseases the First Clinical Medical College Shanxi Medical University Taiyuan Shanxi 030001 China

School of Clinical Medicine Shandong Second Medical University Weifang Shandong 261053 China

CAS Engineering Laboratory for Nanozyme Key Laboratory of Biomacromolecules (CAS) CAS Center for Excellence in Biomacromolecules Institute of Biophysics Chinese Academy of Sciences Beijing 100101 China

Nanozyme Laboratory in Zhongyuan Henan Academy of Innovations in Medical Science Zhengzhou Henan 451163 China

Academy of Medical Sciences Tianjian Laboratory of Advanced Biomedical Sciences Zhengzhou University Zhengzhou Henan China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Henan Province · Henan Provincial Science and Technology Research Project · Science and Technology Innovation Talents in Universities of Henan Province

References (36)

Show source-provided references
1. 10.1002/adma.20200212910.1002/adma.202002129 ↗
2. 10.1016/j.jacc.2023.02.03910.1016/j.jacc.2023.02.039 ↗
3. 10.1038/nrcardio.2015.6510.1038/nrcardio.2015.65 ↗
4. 10.1002/advs.20220350510.1002/advs.202203505 ↗
5. 10.1146/annurev-pharmtox-030620-10484210.1146/annurev-pharmtox-030620-104842 ↗
6. 10.1161/CIRCRESAHA.122.32166710.1161/CIRCRESAHA.122.321667 ↗
7. 10.1038/s41569-022-00735-410.1038/s41569-022-00735-4 ↗
8. 10.1038/s41392-023-01606-110.1038/s41392-023-01606-1 ↗
9. 10.1016/j.yjmcc.2022.10.00410.1016/j.yjmcc.2022.10.004 ↗
10. 10.1073/pnas.182102211610.1073/pnas.1821022116 ↗
11. 10.1172/jci.insight.13274710.1172/jci.insight.132747 ↗
12. 10.1038/nature2239310.1038/nature22393 ↗
13. 10.1172/jci.insight.12883410.1172/jci.insight.128834 ↗
14. 10.1161/CIRCRESAHA.120.31650910.1161/CIRCRESAHA.120.316509 ↗
15. 10.1016/j.freeradbiomed.2006.02.02410.1016/j.freeradbiomed.2006.02.024 ↗
16. 10.1172/JCI11890910.1172/JCI118909 ↗
17. 10.1039/D3NR01722B10.1039/D3NR01722B ↗
18. 10.1039/C8CS00457A10.1039/C8CS00457A ↗
19. 10.1021/acsnano.3c0768010.1021/acsnano.3c07680 ↗
20. 10.1016/j.jhazmat.2022.12919910.1016/j.jhazmat.2022.129199 ↗
21. 10.1002/advs.20230597910.1002/advs.202305979 ↗
22. 10.1039/D3CS00673E10.1039/D3CS00673E ↗
23. 10.1002/smll.20220480910.1002/smll.202204809 ↗
24. 10.1021/acsnano.0c0362910.1021/acsnano.0c03629 ↗
25. 10.1016/j.biomaterials.2014.08.03710.1016/j.biomaterials.2014.08.037 ↗
26. 10.1038/s41392-020-00253-010.1038/s41392-020-00253-0 ↗
27. 10.1007/s10787-012-0149-110.1007/s10787-012-0149-1 ↗
28. Mu X. · ACS Nano · 2019 · 13 · 1870
29. 10.1002/adma.20230847710.1002/adma.202308477 ↗
30. 10.1002/advs.20220600710.1002/advs.202206007 ↗
31. 10.1016/S1470-2045(18)30457-110.1016/S1470-2045(18)30457-1 ↗
32. 10.3322/caac.2134110.3322/caac.21341 ↗
33. 10.1038/s41419-022-05460-x10.1038/s41419-022-05460-x ↗
34. 10.1111/imr.1290910.1111/imr.12909 ↗
35. 10.1016/j.cell.2023.05.03910.1016/j.cell.2023.05.039 ↗
36. 10.1038/s41419‐022‐05460‐x10.1038/s41419‐022‐05460‐x ↗